Get started
Author

Martina Raggi

Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study
2022 · Céline Ben Hassen, Aurore Fayosse, et al. · BMJ · 127
Exact parametric causal mediation analysis for a binary outcome with a binary mediator
2021 · Marco Doretti, Martina Raggi, et al. · Statistical Methods & Applications · 28
PDF
Contribution of smoking towards the association between socioeconomic position and dementia: 32-year follow-up of the Whitehall II prospective cohort study
2022 · Martina Raggi, Aline Dugravot, et al. · The Lancet Regional Health - Europe · 18
PDF
Path analysis for binary random variables
2023 · Raggi M., Stanghellini E., et al. · Florence Research (University of Florence) · 6
How Pricing and Ratings Affect Perceived Value of Digital Detox Apps
2023 · Aditya Kumar Purohit, Martina Raggi, et al. · Extended Abstracts of the CHI Conference on Human Factors in Computing Systems (CHI EA) · 4
PDF
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
2025 · Sairah Ahmed, Alejandro Martin Garcia-Sancho, et al. · Blood · 3
PDF
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL
2026 · Sairah Ahmed, Alejandro Martín García-Sancho, et al. · Blood · 1
KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel
2026 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Transplantation and Cellular Therapy · 1
KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel
2025 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Blood · 1
PDF
Extended Treatment-Free Hospitalization-Free Time and Quality of Life Benefits with CAR T-cell Therapy in Subgroups of Patients with relapsed/refractory MM: Insights from the KarMMa-3 Trial
2026 · Krina K. Patel, Lin Wang, et al. · Transplantation and Cellular Therapy
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients with Third-Line or Later (3L+) Follicular Lymphoma (FL) from TRANSCEND FL
2026 · Sairah Ahmed, Alejandro Martin García-Sancho, et al. · Transplantation and Cellular Therapy
Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial
2025 · Krina Patel, Lin Wang, et al. · Blood
POSTER: CT-235 Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)
2025 · Sairah Ahmed, Juan Luis Reguera Ortega, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-235: Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24)
2025 · Sairah Ahmed, Juan Luis Reguera Ortega, et al. · Clinical Lymphoma Myeloma & Leukemia
Path Analysis for Binary Random Variables
2021 · Martina Raggi, Elena Stanghellini, et al. · Sociological Methods & Research
PDF
Mediation analysis for binary random variables : parametric decomposition of the total effect
2020 · Raggi, Martina
Exact parametric causal mediation analysis for non-rare binary outcomes with binary mediators
2018 · Marco Doretti, Martina Raggi, et al. · arXiv (Cornell University)
Works count: 17
Citation count: 189
H-index: 4
I10-index: 3
Year
Topic
Type